Skip to main content

Advertisement

Table 7 First-Line Options for On-Demand Treatment of HAE-1/2

From: WAO Guideline for the Management of Hereditary Angioedema

  Route of administration Efficacy Safety Limitation Self-administration Age, yrs Cost
Berinert IV +++ +++* +† + All (≥12 in the United States) High
Cinryze IV +++ +++* +† + ≥12 High
Ruconest IV +++ +++ +‡ - ≥18 High
Icatibant SC +++ +++ + ≥18 High
Ecallantide SC +++ +++ +|| - > 16 High
  1. IV, intraveneous; SC, subcutaneous.
  2. *Blood product.
  3. †Pretreatment vaccination recommended.
  4. ‡Pretreatment and repeated allergological testing required.
  5. §Special attention required in acute ischemic heart disease/unstable angina and in the first week after cerebral infarction.
  6. ¶Three injections.
  7. ||Posttreatment observation/keep refrigerated.